about
The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrumCutaneous dermatomyositis: an updated review of treatment options and internal associations.Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.Health-related quality of life in morphoeaQuality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus.Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic ReviewValidation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositisFrom pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Correlates of self-reported quality of life in adults and children with morpheaChronic Pruritus and Connective Tissue Disorders: Review, Gaps, and Future Directions.A systematic review of patient-reported outcomes in patients with cutaneous lupus erythematosus.Predictors of Reduced Health-Related Quality of Life in Adult Patients with Idiopathic Inflammatory Myopathies.The impact of adverse reactions to injectable filler substances on quality of life: results from the Berlin Injectable Filler Safety (IFS) - study.Quality of life in adults with facial port-wine stains.Measurement of disease severity in cutaneous autoimmune diseases.Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets.213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.The systemic management of cutaneous dermatomyositis: Results of a stepwise strategy.Quality of life correlates with muscle strength in patients with dermato- or polymyositis.Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.Validation of the Comprehensive International Classification of Functioning, Disability and Health (ICF) Core Set for Diabetes Mellitus in patients with diabetic nephropathy.Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study
P2860
Q27014908-DD62429B-F24D-43DF-9D6A-68016FAC7F4EQ34349952-A9680017-F52D-44E5-91FF-AF1BE472048EQ35097253-24DE0D54-BD02-403A-84F6-071A42F8B91AQ35498937-3FD41751-C2E7-442A-B477-734A16177954Q35602574-B62D2AB2-6366-430E-9DEA-4010EBC23102Q35743200-1569A9C6-FDBA-4891-B59E-AC97AE9646A2Q36098608-999669DB-E0BD-4197-A83C-6974A3B91D51Q36932360-BE818049-01E0-4689-B57E-4D920725BDA7Q36932367-56362F31-A94A-4F48-94F6-DC969436D1FEQ37038527-E83F0112-7355-4E40-B564-6B0C1D4A8CC3Q37368405-8042C698-5F7E-48B3-9AB1-F3782C68027FQ37710940-E8D45CD6-E42D-4A31-9D83-FE6437755085Q38853403-6B646488-D814-4549-B173-A0CFDA239E29Q38896851-2F90FA58-6EBA-412C-B8A9-292B71788A45Q39001637-DB659DEF-4D23-4E55-812E-3C5CACFAB406Q39967666-6299DBD9-9B5C-4337-BDE8-693F4FBCB297Q40428571-A5C4F616-833F-4631-BE1B-ED9371180129Q41558860-AF6AF048-7279-4F4A-9EE8-D53A12A8022AQ42290856-376C59F6-E05C-4B21-BA73-7A6BC9D50A18Q42365042-0CD0F297-5B8D-4719-A9DE-9985FF1C9BECQ46134512-722DFD69-4B7A-404F-9A69-BFBB458298D7Q47103957-C1568537-2A2E-4641-80E6-C766E739841CQ47702601-A8D2181F-E43D-4152-90CB-30F9258A0B60Q47760514-5D4B5EC4-E443-44E9-BA04-86C0884358C7Q51549029-9DC7F0B3-34E6-4B38-9364-B09B37834536Q51833656-2C5135B2-DAB9-460E-9327-C894391128FDQ57927779-E92C8EE0-67C3-44A9-B0C5-6F08C16EAB87
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Quality of life in dermatomyositis.
@ast
Quality of life in dermatomyositis.
@en
type
label
Quality of life in dermatomyositis.
@ast
Quality of life in dermatomyositis.
@en
prefLabel
Quality of life in dermatomyositis.
@ast
Quality of life in dermatomyositis.
@en
P2093
P2860
P1476
Quality of life in dermatomyositis.
@en
P2093
Joyce Okawa
Kristen Foering
Monika Chock
Renato Goreshi
Victoria Werth
P2860
P304
P356
10.1016/J.JAAD.2010.10.016
P407
P577
2011-07-01T00:00:00Z